Abstract: Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through and inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing PTCs.

Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. In some embodiments, the methods involve generating an immune response in an individual by inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells. In one embodiment, a method of treating cancer in a subject includes administering amlexanox in combination with immune modulators, such as checkpoint inhibitors, immune co-stimulatory molecules, TLR agonists, and TNFR superfamily agonists. In one embodiment, the checkpoint inhibitors are selected from antibodies against PD-1, PD-L1, and CTLA-4.

Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. In some embodiments, the methods involve generating an immune response in an individual by inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells. In one embodiment, a method of treating cancer in a subject includes administering amlexanox in combination with immune modulators, such as checkpoint inhibitors, immune co-stimulatory molecules, TLR agonists, and TNFR superfamily agonists. In one embodiment, the checkpoint inhibitors are selected from antibodies against PD-1, PD-L1, and CTLA-4.

Abstract: Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through and inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing PTCs.

Abstract: Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through and inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing PTCs.

Abstract: Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing premature termination codons (PTCs).

Abstract: Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through of messenger RNAs (mRNAs) bearing PTCs.

Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. In some embodiments, the methods involve generating an immune response in an individual by inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells. In one embodiment, a method of treating cancer in a subject includes administering amlexanox in combination with immune modulators, such as checkpoint inhibitors, immune co-stimulatory molecules, TLR agonists, and TNFR superfamily agonists. In one embodiment, the checkpoint inhibitors are selected from antibodies against PD-1, PD-L1, and CTLA-4.

Abstract: Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through and inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing PTCs.

Abstract: Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through of messenger RNAs (mRNAs) bearing PTCs.

Abstract: Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing premature termination codons (PTCs).

Abstract: The presently disclosed subject matter relates to biomarkers allowing for improved diagnosis and prognosis of alopecia areata as well as effective treatments for the disease, including methods that incorporate biomarkers capable of identifying patient sub-populations that will respond to such treatments and methods that incorporate biomarkers capable of tracking the progress of such treatments.

Abstract: The presently disclosed subject matter relates, in certain embodiments, to compositions and methods for the inhibition of the JAK-STAT pathway in order to induce hair growth. In certain embodiments, the presently disclosed subject matter relates to topical treatments with small molecule inhibitors of the JAK-STAT pathway to induce hair growth.

Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a FGF13 inhibitor. The invention further provides for methods for treating a hair growth disorder in a subject by administering a FGF13 activator.

Abstract: Methods for inhibition of hairless protein mRNA using RNA interference is described, in particular methods for hair removal. Also described are nucleic acid constructs for RNAi-mediated inhibition of hairless protein mRNA and compositions including such constructs.

Abstract: The present invention provides for methods of inhibiting hair growth, comprising decreasing the level of TRPS1 mRNA and/or protein in hair follicle cells of a subject. The present invention also provides for methods of promoting hair growth, comprising increasing the level of TRPS1 mRNA and/or protein in hair follicle cells of a subject. The level of TRPS1 may be decreased or increased either directly, for example by introducing, into a hair follicle cell, a TRPS1 mRNA or protein. Alternatively, the level of TRPS1 may be decreased or increased indirectly, by providing an agent that results in decreased or increased expression of an endogenous TRPS1 gene. The invention also provides for transgenic animals with aberrancies in TRPS1 expression, and for assay systems (including transgenic animals and cell-based systems) that may be used to identify agents that decrease or increase TRPS1 expression.

Abstract: Methods for inhibition of hairless protein mRNA using RNA interference is described, in particular methods for hair removal. Also described are nucleic acid constructs for RNAi-mediated inhibition of hairless protein mRNA and compositions including such constructs.

Abstract: Methods for inhibition of desmoglein 4 and nude protein mRNA using RNA interference are described, in particular methods for inhibition or hair growth or hair removal. Also described are nucleic acid constructs for RNAi-mediated inhibition of desmoglein 4 and nude protein mRNA and compositions including such constructs.

Abstract: This invention provides methods and compositions for inhibiting the expression of desmoglein 4. This invention also provides pharmaceutical compositions for inhibiting hair growth in a subject.

Abstract: This invention relates to compounds, compositions, and methods useful for modulating retinoblastoma (RB1) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of retinoblastoma gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of retinoblastoma genes.